|
Product name
|
Alprostadil
|
|
Molecular Formula
|
C20H34O5
|
|
Molecular Weight
|
354.48
|
|
CAS No.
|
745-65-3
|
|
Quality Standard
|
95% up, USP26
|
|
Appearance
|
White powder
|
|
Items
|
Specifications
|
Results
|
|
Appearance
|
White to
off-white powder
|
Complies
|
|
Identification
|
HPLC retention
time of sample complies with that of known sample
|
Complies
|
|
Water
|
≤0.5%
|
0.03%
|
|
Residual
solvents
|
≤0.5%
|
0.02%
|
|
Residual on
ignition
|
≤0.5%
|
0.20%
|
|
Related
substances
|
PGAI:≤0.5%
|
Undetected
|
|
PGBI:≤0.5%
|
Undetected
|
|
13,14-Dihydro-PGEI:
≤0.5%
|
Undetected
|
|
Other
impurities: ≤ 0.5%
|
Undetected
|
|
Assay
|
95.0%~105.0%
|
99.00%
|
Function of Alprostadil
Alprostadil, alias PGE1. PGE1 is a biologically active substance widely present in the body,
the mechanism of treating diabetic neuropathy:
1. Improve hemodynamics, increase the
CAMP content in vascular smooth muscle cells, exert its vasodilator effect and
reduce peripheral resistance;
2. To improve blood rheology, PGE can
inhibit platelet aggregation, reduce platelet high response and thromboxane A
(TXA) level, inhibit platelet activation, promote the reversal of activated
platelets around thrombus, and improve the deformability of red blood cells;
3. PGE can activate lipoproteinase and
promote triglyceride hydrolysis, reduce blood lipids and blood viscosity;
4. PGE can stimulate vascular
endothelial cells to produce tissue-type fibrinolytic substance (t-PA), which
has a certain direct thrombolytic effect.
5. By inhibiting free Caz of vascular
smooth muscle cells and inhibiting the release of norepinephrine from vascular
sympathetic nerve endings, the vascular smooth muscle is relaxed and the
microcirculation is improved.
